Company news
Collplant Biotechnologies Ltd. (NASDAQ:CLGN) news
Every Collplant Biotechnologies Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
COLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
September 30, 2026
LightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
September 24, 2026
CollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 22, 2026
CollPlant to Host LightSolver Investor Webinar on September 17, 2026
September 10, 2026
COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
September 7, 2026
COLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
September 3, 2026
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
September 1, 2026
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
June 30, 2026
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
May 29, 2026
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
March 25, 2026
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
March 23, 2026
CollPlant Biotechnologies Launches Redesigned Corporate Website
March 17, 2026
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
March 10, 2026
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler
February 25, 2026
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
February 22, 2026
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
February 17, 2026
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
February 5, 2026
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
November 26, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS
November 18, 2025
CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada
October 27, 2025
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology
October 20, 2025
First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk
October 16, 2025
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler
September 30, 2025
CollPlant Expands the Distribution of its VergenixSTR Product in Europe
September 15, 2025
CollPlant to Present at the 2025 International Conference on Biofabrication
September 2, 2025
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
August 25, 2025
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
August 20, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS
August 5, 2025
CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations
July 14, 2025
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
June 9, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
June 4, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
May 30, 2025
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
May 28, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
May 14, 2025
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
April 15, 2025
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
March 26, 2025
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
March 19, 2025
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
February 24, 2025
CollPlant Biotechnologies Provides a Corporate Update
February 11, 2025
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
November 26, 2024
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
November 11, 2024
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
August 19, 2024
CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants
August 18, 2024
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION
August 5, 2024
CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
July 28, 2024
CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data
June 5, 2024
CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update
May 28, 2024
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
May 15, 2024
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
April 3, 2024
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
March 25, 2024